ATE148348T1 - Behandlung von einer autoimmun-krankheit - Google Patents
Behandlung von einer autoimmun-krankheitInfo
- Publication number
- ATE148348T1 ATE148348T1 AT90913991T AT90913991T ATE148348T1 AT E148348 T1 ATE148348 T1 AT E148348T1 AT 90913991 T AT90913991 T AT 90913991T AT 90913991 T AT90913991 T AT 90913991T AT E148348 T1 ATE148348 T1 AT E148348T1
- Authority
- AT
- Austria
- Prior art keywords
- segment
- immunoglobulin
- migis
- suppression
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40812389A | 1989-09-15 | 1989-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE148348T1 true ATE148348T1 (de) | 1997-02-15 |
Family
ID=23614953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90913991T ATE148348T1 (de) | 1989-09-15 | 1990-09-14 | Behandlung von einer autoimmun-krankheit |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0493446B1 (de) |
JP (1) | JP2852705B2 (de) |
AT (1) | ATE148348T1 (de) |
AU (1) | AU639719B2 (de) |
CA (1) | CA2065414C (de) |
DE (1) | DE69029858T2 (de) |
DK (1) | DK0493446T3 (de) |
ES (1) | ES2100892T3 (de) |
WO (1) | WO1991004055A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
DE69324579T2 (de) * | 1992-03-17 | 1999-09-23 | Novartis Ag | Gentechnologisch hergestellte antikörper |
CU22585A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
DE10127712A1 (de) * | 2001-06-07 | 2002-12-19 | Torsten Witte | Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis |
US8137670B2 (en) | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
CA2734340C (en) | 2008-08-28 | 2019-03-05 | Novartis Ag | Cell surface display of polypeptide isoforms by stop codon readthrough |
JP5848133B2 (ja) | 2009-02-25 | 2016-01-27 | アカデミア シニカAcademia Sinica | Bリンパ球上のヒトmIgEに結合可能な抗CεmX抗体 |
EP3626254A1 (de) * | 2012-03-16 | 2020-03-25 | University Health Network | Lösliches toso protein und dessen verwendung zur behandlung von autoimmunerkrankungen |
CN104603150A (zh) | 2012-04-20 | 2015-05-06 | 中央研究院 | 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 |
EP3077010B1 (de) * | 2013-12-03 | 2020-04-01 | Welt Bio-Molecular Pharmaceutical LLC | Antikörper für membrangebundes b-zellrezeptorkomplex-igm und verwendung dieser antikörpe |
CN106029092B (zh) * | 2013-12-05 | 2019-11-19 | 中央研究院 | 能够溶解带有膜锚定型免疫球蛋白a的b淋巴球与降低免疫球蛋白a生产的抗人类膜锚定型免疫球蛋白a抗体 |
CN111741768A (zh) | 2017-10-31 | 2020-10-02 | 合一生技股份有限公司 | 治疗IgE介导的过敏性疾病 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4661586A (en) * | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
US4545986A (en) * | 1982-06-22 | 1985-10-08 | Research Corporation | Timothy grass antigen specific anti-idiotypic antibodies |
SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD230879B1 (de) * | 1983-09-08 | 1987-06-17 | Univ Leipzig | Verfahren zur herstellung monoklonaler antikoerper fuer human-igm |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
JPS6468398A (en) * | 1987-09-08 | 1989-03-14 | Agency Ind Science Techn | Monoclonal anti-idiotype antibody and hybridoma and use thereof |
JP2724625B2 (ja) * | 1987-12-31 | 1998-03-09 | タノックス・バイオシステムズ・インコーポレーテッド | IgE産出性Bリンパ球上の独特な抗原決定基 |
-
1990
- 1990-09-14 AU AU64376/90A patent/AU639719B2/en not_active Ceased
- 1990-09-14 ES ES90913991T patent/ES2100892T3/es not_active Expired - Lifetime
- 1990-09-14 JP JP2513077A patent/JP2852705B2/ja not_active Expired - Fee Related
- 1990-09-14 CA CA002065414A patent/CA2065414C/en not_active Expired - Fee Related
- 1990-09-14 AT AT90913991T patent/ATE148348T1/de not_active IP Right Cessation
- 1990-09-14 EP EP90913991A patent/EP0493446B1/de not_active Expired - Lifetime
- 1990-09-14 WO PCT/US1990/005229 patent/WO1991004055A1/en active IP Right Grant
- 1990-09-14 DE DE69029858T patent/DE69029858T2/de not_active Expired - Fee Related
- 1990-09-14 DK DK90913991.7T patent/DK0493446T3/da active
Also Published As
Publication number | Publication date |
---|---|
ES2100892T3 (es) | 1997-07-01 |
EP0493446A4 (en) | 1993-03-31 |
JPH05503687A (ja) | 1993-06-17 |
WO1991004055A1 (en) | 1991-04-04 |
DK0493446T3 (da) | 1997-08-11 |
DE69029858D1 (de) | 1997-03-13 |
AU639719B2 (en) | 1993-08-05 |
EP0493446B1 (de) | 1997-01-29 |
JP2852705B2 (ja) | 1999-02-03 |
CA2065414C (en) | 2007-05-15 |
AU6437690A (en) | 1991-04-18 |
CA2065414A1 (en) | 1991-03-16 |
EP0493446A1 (de) | 1992-07-08 |
DE69029858T2 (de) | 1997-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO982062L (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
ATE148348T1 (de) | Behandlung von einer autoimmun-krankheit | |
WO1998057994A3 (en) | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria | |
ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
DE69527975T2 (de) | Humanisierte antikörper gegen cd38 | |
DE69429095T2 (de) | Humanisierte antikoerper | |
DE69932084D1 (de) | Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen | |
RU94045826A (ru) | Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i | |
ATE166230T1 (de) | Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock | |
NO157145C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive n-glykosylerte karboksylsyreamidderivater. | |
CY2583B2 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
DE60014239D1 (de) | Reinigungsverfahren von verbindeten Ig Fraktionen mit immunomodulierender Aktivität | |
DE69125485T2 (de) | Verfahren und zwischenprodukte synthetischer antikörperderivate | |
NO943653L (no) | Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon | |
ATE401912T1 (de) | Methoden der zubereitung von immunglobulin und dessen verwendungen | |
KR890016165A (ko) | 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도 | |
ATE122100T1 (de) | Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen. | |
FR2571146B1 (fr) | Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant | |
KR890700133A (ko) | 인체단일클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료제 | |
DE69330884T2 (de) | Behandlung von unfruchtbarkeit und steigerung der befruchtungsfähigkeit männlicher säugetiere durch thymosin-peptid und seine antikörper | |
RU93035807A (ru) | Способ лечения юношеского эпифизиолиса |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |